Global Refractory Follicular Lymphoma Diagnostics Market Projected to Reach USD 464.47 Million by 2029 Refractory Follicular ...

LMNTIC Biotech develops liquid biopsy technology to isolate rare tumor cells in blood LMNTIC Biotech pioneers novel ...

In a study involving 43 MBC patients, the liquid biopsy test reclassified three out of five patients who were initially deemed HER2-negative by tissue biopsy as HER2-positive. This discovery ...

Abu Dhabi health chiefs have hailed the introduction of a blood test for colon cancer as a "game-changer" in the emirate's ...

The prevalence of cancer is escalating at an alarming rate globally, underscoring the need for robust diagnostic solutions. Factors such as growing awareness, supportive government initiatives, and ...

Dong-A ST secures European approval for autoimmune treatment Immuldosa Dong-A ST gains EU clearance for its innovative ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing ...

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutionsLOS ANGELES, ...

Guardant Health (GH) announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the ...